From Yahoo Finance: 2025-04-28 07:32:00

Revvity beats Wall Street estimates in Q1 with a profit forecast of $4.90 to $5 per share. Revenue outlook raised to $2.83 billion to $2.87 billion. Analysts praise the company’s performance. Biotech sector funding concerns linger due to policy uncertainty. Revvity shares down 15.5% this year.

CEO Prahlad Singh optimistic about Revvity’s performance for the year despite macroeconomic challenges. Larger competitors Thermo Fisher Scientific and Danaher also post strong results but warn of potential impacts from tariffs and uncertainty. Revvity’s life sciences unit revenue surpasses estimates at $340.4 million.

Revvity’s first-quarter adjusted profit of $1.01 per share exceeds analysts’ expectations. Company reports revenue of $664.8 million, slightly above estimates. Reagents and instruments unit revenue reaches $340.4 million, beating estimates. Steady demand from biotech clients boosts performance. Shares decline 15.5% this year.

Read more: Revvity beats quarterly estimates on steady demand for medical equipment